InterVenn Biosciences today announced that Padmanee Sharma, MD, PhD, has joined the Company’s Board of Advisors, effective March 9, 2021. Dr. Sharma joins the InterVenn Board of Advisors with extensive experience in basic and clinical immunology and cancer research.
Dr. Sharma is Professor in the Departments of Genitourinary Medical Oncology and Immunology and holds the T.C. and Jeanette Hsu Endowed Chair in Cell Biology in the Division of Cancer Medicine at MD Anderson Cancer Center. Her translational research focuses on learning how to apply immune-based therapeutic strategies to manipulate components of the human immune system to lead to tumor regression. She has designed and led or participated in more than 50 clinical trials of cancer vaccines and other immune-based treatments, specifically in the area of prostate cancer where she has explored differences in T cell subsets and function between pre- and post-therapy blood and tissue specimens. She also conducts laboratory research as part of her ongoing studies aimed at understanding how immunotherapy affects the immune system and tumor biology, in close collaboration with Dr. James P. Allison, who is also joining the InterVenn Board of Advisors. Dr. Sharma is a member of the scientific review panel for the Cancer Research Institute, the oldest institution dedicated to immuno-oncology research.
Dr. Sharma has won multiple awards during her career including the Emil Frei III Award for Excellence in Translational Research in 2016 and was inducted into the American Society for Clinical Investigation in 2018. She is the recipient of the 2018 William B. Coley Award for Distinguished Research in Tumor Immunology.
Dr. Sharma is a practicing physician who is driven by a deep commitment and dedication to her patients for whom she is not only a physician, but a very personal source of strength and confidence as she manages their care.
“We are extremely grateful to welcome Pam to our Board of Advisors,” said Aldo Carrascoso, Co-Founder and Chief Executive Officer of InterVenn Biosciences. “Pam’s leadership in the field of immunotherapy and her deep knowledge and experience in translational immuno-oncology research and clinical practice bring tremendous value to InterVenn. Her expertise and guidance will greatly benefit InterVenn this year and in the years to come.”
About InterVenn Biosciences
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.